The therapeutic use of AM and b-FGF as they have a direct impact on the peripheral blood flow, angiogenic and anti-inflammatory factors in the future may be prospective , they may be used to reduce the morbidity of cardiovascular and cerebrovascular attacks in diabetes through normalizing vascular endothelium function. The gene discussed is FGF2; the disease is diabetes mellitus.